Bacil Pharma Ltd.
|
Ratio Analysis
|
|
You can view the
Ratio Analysis
for the last 5 years.
Market Cap. (Rs.)
|
11.94 Cr.
|
P/BV
|
25.87
|
Book Value (Rs.)
|
0.78
|
52 Week High/Low (Rs.)
|
20/5
|
FV/ML
|
10/1
|
P/E(X)
|
0.00
|
Bookclosure
|
16/09/2023
|
EPS (Rs.)
|
0.00
|
Div Yield (%)
|
0.00
|
|
Months | 12 | 12 | 12 | 12 | 12 |
Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR | AR | AR |
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| | | | | |
PER SHARE RATIOS | | | | | |
| | | | | |
Basic EPS (Rs.) | -0.17 | -6.55 | -0.41 | -0.54 | -0.58 |
Diluted EPS (Rs.) | -0.17 | -6.55 | -0.41 | -0.54 | -0.58 |
Cash EPS (Rs.) | -0.15 | -5.91 | -0.35 | -0.47 | -0.51 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 1.68 | 1.88 | 2.13 | 2.12 | 2.93 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 1.68 | 1.88 | 2.13 | 2.12 | 2.93 |
PBDIT / Share (Rs.) | -0.15 | -5.91 | -0.35 | -0.47 | -0.51 |
PBIT / Share (Rs.) | -0.15 | -5.91 | -0.36 | -0.48 | -0.52 |
PBT / Share (Rs.) | -0.15 | -5.91 | -0.36 | -0.48 | -0.52 |
Net Profit / Share (Rs.) | -0.15 | -5.91 | -0.36 | -0.48 | -0.52 |
Return on Networth / Equity (%) | -9.26 | -315.24 | -17.19 | -22.73 | -17.91 |
Return on Capital Employeed (%) | -9.26 | -315.26 | -17.22 | -22.76 | -17.97 |
Return On Assets (%) | -9.03 | -303.54 | -5.85 | -7.67 | -7.51 |
Total Debt / Equity (X) | 0.01 | 0.02 | 0.12 | 0.12 | 0.04 |
| | | | | |
LIQUIDITY RATIOS | | | | | |
| | | | | |
Current Ratio (X) | 8.19 | 10.63 | 1.04 | 1.02 | 1.16 |
Quick Ratio (X) | 8.19 | 10.63 | 1.04 | 1.02 | 1.16 |
| | | | | |
VALUATION RATIOS | | | | | |
| | | | | |
Enterprise Value (Cr.) | 3.57 | 3.54 | 2.11 | 1.20 | 1.51 |
EV / EBITDA (X) | -35.97 | -0.91 | -9.00 | -3.91 | -4.51 |
Price / BV (X) | 3.25 | 3.06 | 1.46 | 0.77 | 0.78 |
EarningsYield | -0.02 | -1.03 | -0.11 | -0.29 | -0.22 |